vs
EXACT SCIENCES CORP（EXAS）与Toast, Inc.（TOST）财务数据对比。点击上方公司名可切换其他公司
Toast, Inc.的季度营收约是EXACT SCIENCES CORP的1.9倍（$1.6B vs $878.4M），Toast, Inc.净利率更高（6.2% vs -9.8%，领先16.0%），EXACT SCIENCES CORP同比增速更快（23.1% vs 22.0%），Toast, Inc.自由现金流更多（$178.0M vs $120.4M），过去两年Toast, Inc.的营收复合增速更高（23.3% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Toast, Inc.是总部位于美国马萨诸塞州波士顿的云餐饮管理软件企业，主打基于安卓操作系统研发的一体化销售点（POS）系统，可为餐饮商家提供涵盖收银、订单管理等在内的全场景门店经营解决方案。
EXAS vs TOST — 直观对比
营收规模更大
TOST
是对方的1.9倍
$878.4M
营收增速更快
EXAS
高出1.1%
22.0%
净利率更高
TOST
高出16.0%
-9.8%
自由现金流更多
TOST
多$57.6M
$120.4M
两年增速更快
TOST
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.6B |
| 净利润 | $-86.0M | $101.0M |
| 毛利率 | 70.1% | 25.9% |
| 营业利润率 | -9.4% | 5.2% |
| 净利率 | -9.8% | 6.2% |
| 营收同比 | 23.1% | 22.0% |
| 净利润同比 | 90.1% | 215.6% |
| 每股收益（稀释后） | $-0.45 | $0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASTOST
| Q4 25 | $878.4M | $1.6B | ||
| Q3 25 | $850.7M | $1.6B | ||
| Q2 25 | $811.1M | $1.6B | ||
| Q1 25 | $706.8M | $1.3B | ||
| Q4 24 | $713.4M | $1.3B | ||
| Q3 24 | $708.7M | $1.3B | ||
| Q2 24 | $699.3M | $1.2B | ||
| Q1 24 | $637.5M | $1.1B |
净利润EXASTOST
| Q4 25 | $-86.0M | $101.0M | ||
| Q3 25 | $-19.6M | $105.0M | ||
| Q2 25 | $-1.2M | $80.0M | ||
| Q1 25 | $-101.2M | $56.0M | ||
| Q4 24 | $-864.6M | $32.0M | ||
| Q3 24 | $-38.2M | $56.0M | ||
| Q2 24 | $-15.8M | $14.0M | ||
| Q1 24 | $-110.2M | $-83.0M |
毛利率EXASTOST
| Q4 25 | 70.1% | 25.9% | ||
| Q3 25 | 68.6% | 26.5% | ||
| Q2 25 | 69.3% | 25.3% | ||
| Q1 25 | 70.8% | 25.9% | ||
| Q4 24 | 69.0% | 24.9% | ||
| Q3 24 | 69.4% | 24.7% | ||
| Q2 24 | 69.8% | 23.0% | ||
| Q1 24 | 70.0% | 23.2% |
营业利润率EXASTOST
| Q4 25 | -9.4% | 5.2% | ||
| Q3 25 | -3.0% | 5.1% | ||
| Q2 25 | -0.3% | 5.2% | ||
| Q1 25 | -13.6% | 3.2% | ||
| Q4 24 | -122.8% | 2.5% | ||
| Q3 24 | -5.6% | 2.6% | ||
| Q2 24 | -3.8% | 0.4% | ||
| Q1 24 | -16.7% | -5.2% |
净利率EXASTOST
| Q4 25 | -9.8% | 6.2% | ||
| Q3 25 | -2.3% | 6.4% | ||
| Q2 25 | -0.1% | 5.2% | ||
| Q1 25 | -14.3% | 4.2% | ||
| Q4 24 | -121.2% | 2.4% | ||
| Q3 24 | -5.4% | 4.3% | ||
| Q2 24 | -2.3% | 1.1% | ||
| Q1 24 | -17.3% | -7.7% |
每股收益（稀释后）EXASTOST
| Q4 25 | $-0.45 | $0.18 | ||
| Q3 25 | $-0.10 | $0.16 | ||
| Q2 25 | $-0.01 | $0.13 | ||
| Q1 25 | $-0.54 | $0.09 | ||
| Q4 24 | $-4.69 | $0.09 | ||
| Q3 24 | $-0.21 | $0.07 | ||
| Q2 24 | $-0.09 | $0.02 | ||
| Q1 24 | $-0.60 | $-0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.1B |
| 总资产 | $5.9B | $3.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASTOST
| Q4 25 | $964.7M | $1.4B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $858.4M | $1.2B | ||
| Q1 25 | $786.2M | $1.0B | ||
| Q4 24 | $1.0B | $903.0M | ||
| Q3 24 | $1.0B | $761.0M | ||
| Q2 24 | $946.8M | $691.0M | ||
| Q1 24 | $652.1M | $578.0M |
股东权益EXASTOST
| Q4 25 | $2.4B | $2.1B | ||
| Q3 25 | $2.5B | $2.0B | ||
| Q2 25 | $2.5B | $1.8B | ||
| Q1 25 | $2.4B | $1.7B | ||
| Q4 24 | $2.4B | $1.5B | ||
| Q3 24 | $3.2B | $1.4B | ||
| Q2 24 | $3.2B | $1.3B | ||
| Q1 24 | $3.1B | $1.2B |
总资产EXASTOST
| Q4 25 | $5.9B | $3.1B | ||
| Q3 25 | $5.9B | $3.0B | ||
| Q2 25 | $5.8B | $2.8B | ||
| Q1 25 | $5.7B | $2.6B | ||
| Q4 24 | $5.9B | $2.4B | ||
| Q3 24 | $6.7B | $2.2B | ||
| Q2 24 | $6.7B | $2.2B | ||
| Q1 24 | $6.4B | $2.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $194.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $178.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 10.9% |
| 资本支出强度资本支出/营收 | 3.6% | 1.0% |
| 现金转化率经营现金流/净利润 | — | 1.92× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $608.0M |
8季度趋势，按日历期对齐
经营现金流EXASTOST
| Q4 25 | $151.7M | $194.0M | ||
| Q3 25 | $219.9M | $165.0M | ||
| Q2 25 | $89.0M | $223.0M | ||
| Q1 25 | $30.8M | $79.0M | ||
| Q4 24 | $47.1M | $147.0M | ||
| Q3 24 | $138.7M | $109.0M | ||
| Q2 24 | $107.1M | $124.0M | ||
| Q1 24 | $-82.3M | $-20.0M |
自由现金流EXASTOST
| Q4 25 | $120.4M | $178.0M | ||
| Q3 25 | $190.0M | $153.0M | ||
| Q2 25 | $46.7M | $208.0M | ||
| Q1 25 | $-365.0K | $69.0M | ||
| Q4 24 | $10.7M | $134.0M | ||
| Q3 24 | $112.6M | $97.0M | ||
| Q2 24 | $71.2M | $108.0M | ||
| Q1 24 | $-120.0M | $-33.0M |
自由现金流率EXASTOST
| Q4 25 | 13.7% | 10.9% | ||
| Q3 25 | 22.3% | 9.4% | ||
| Q2 25 | 5.8% | 13.4% | ||
| Q1 25 | -0.1% | 5.2% | ||
| Q4 24 | 1.5% | 10.0% | ||
| Q3 24 | 15.9% | 7.4% | ||
| Q2 24 | 10.2% | 8.7% | ||
| Q1 24 | -18.8% | -3.1% |
资本支出强度EXASTOST
| Q4 25 | 3.6% | 1.0% | ||
| Q3 25 | 3.5% | 0.7% | ||
| Q2 25 | 5.2% | 1.0% | ||
| Q1 25 | 4.4% | 0.7% | ||
| Q4 24 | 5.1% | 1.0% | ||
| Q3 24 | 3.7% | 0.9% | ||
| Q2 24 | 5.1% | 1.3% | ||
| Q1 24 | 5.9% | 1.2% |
现金转化率EXASTOST
| Q4 25 | — | 1.92× | ||
| Q3 25 | — | 1.57× | ||
| Q2 25 | — | 2.79× | ||
| Q1 25 | — | 1.41× | ||
| Q4 24 | — | 4.59× | ||
| Q3 24 | — | 1.95× | ||
| Q2 24 | — | 8.86× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
TOST
| Technology Service | $1.3B | 82% |
| License | $256.0M | 16% |
| Product And Professional Services | $43.0M | 3% |
